Amyloid cardiomyopathy is characterized by the accumulation of a protein-polysaccharide complex in the tissues of the heart (amyloid), causing myocardial hypertrophy, disrupting its contractility, causing the development of chronic circulatory failure, arrhythmias and other disorders of the heart. Most often, a diagnosis can only be established in the later stages, with the appearance of severe symptoms, when treatment is almost impossible. Scientists from the Peoples' Friendship University of Russia (RUDN) have developed a method that will help determine the development of amyloid myocardiopathy in the early stages, as the online publication for girls and women from 14 to 35 years old Pannochka. net The absence of stable symptoms does not allow to correctly determine the presence of amyloidosis in a patient. Mistakenly at first, the diagnosis is most often made: coronary heart disease. RUDN experts were able to prove that the presence of chronic kidney disease (CKD) may also indicate the development of AL-amyloidosis.

A study by university researchers Vilen Rameev and Aiten Safarov with 55 volunteers who were diagnosed with AL amyloidosis determined an increase in the level of N TproBNR protein in the blood. Changes in the amount of this protein indicate decompensation of the heart. Along with testing heart function, experts conducted a study of kidney function..

The results of the study showed a deterioration of the cardiovascular system in the presence of severe CKD. Slight renal impairment did not cause progression of amyloidosis. Thus, scientists were able to establish that testing kidney function will allow the early stages to determine the development of AL amyloidosis in patients with impaired heart function and reduce the risks of death from this disease.

med-heal. ru.